Kevzara

Sarilumab, the active ingredient in Kevzara, is a IL-6 receptor antagonist presented as a 150 mg per 1.5 mL prefilled syringe solution for subcutaneous use. It treats rheumatoid arthritis in adult patients, reducing inflammation and disease progression.

GNH USA supplies Kevzara as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kevzara acts on the interleukin‑6 signaling pathway to manage inflammatory joint disease.

Rheumatoid arthritis: reduces disease activity, slows joint damage and improves functional outcomes in adult patients.

Common Side Effects: - Injection site reactions such as redness, swelling or pain. - Neutropenia (reduced neutrophil count). - Elevated liver enzymes (ALT, AST). - Headache. - Diarrhea. - Upper respiratory tract infections.

Serious or Rare Side Effects: - Serious infections, including bacterial, fungal or viral. - Severe allergic reactions, including anaphylaxis. - Gastrointestinal perforation or ulceration.

Patients should be monitored for infection risk and laboratory abnormalities during therapy.

Infection screening: assess for active or latent tuberculosis before initiating treatment. Liver monitoring: check hepatic enzymes regularly. Neutrophil count: perform complete blood counts to detect neutropenia. Concurrent immunosuppression: evaluate the need for dose adjustments when used with other immunosuppressants. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sarilumab may interact with other agents that affect immune function or drug metabolism.

Major Interactions (Avoid): - Live or attenuated vaccines: may cause infection due to immunosuppression. - Concurrent use of other IL‑6 pathway inhibitors: increased risk of severe immunosuppression.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sarilumab exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce sarilumab exposure. - Other biologic agents: monitor for additive immunosuppressive effects.